金城醫藥(300233.SZ):金城泰爾氯諾昔康生產線順利通過藥品GMP符合性檢查
格隆匯11月25日丨金城醫藥(300233.SZ)公佈,公司全資子公司北京金城泰爾製藥有限公司(以下簡稱“金城泰爾”)收到北京市藥品監督管理局核准簽發的《藥品GMP符合性檢查吿知書》(編號:京藥監藥GMP[2024]020072)。
檢查範圍及相關生產車間、生產線:氯諾昔康(登記號:Y20220000707)(河北
省滄州市臨港經濟技術開發區西區北京醫藥產業園經五路以東緯二路以北,一車
間:氯諾昔康生產線)。
氯諾昔康(Lornoxicam)為解熱鎮痛、非甾體抗炎藥,是替諾昔康的氯化物。其作用與替諾昔康相似,具有鎮痛、抗炎和解熱作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.